Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
29.43
+0.07 (0.24%)
At close: Mar 6, 2026, 4:00 PM EST
29.72
+0.29 (0.99%)
After-hours: Mar 6, 2026, 7:53 PM EST
Celldex Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 1.55 | 7.02 | 6.88 | 2.36 | 4.65 | |
| Revenue Growth (YoY) | -77.99% | 1.99% | 192.02% | -49.32% | -37.30% | |
| Cost of Revenue | 245.07 | 163.55 | 118.01 | 82.26 | 53.31 | |
| Gross Profit | -243.53 | -156.53 | -111.13 | -79.9 | -48.66 | |
| Selling, General & Admin | 43.84 | 38.55 | 30.91 | 27.2 | 20.49 | |
| Operating Expenses | 43.84 | 38.55 | 30.91 | 27.2 | 20.49 | |
| Operating Income | -287.37 | -195.08 | -142.04 | -107.1 | -69.15 | |
| Interest & Investment Income | 28.61 | 37.22 | 13.11 | 2.91 | 0.51 | |
| EBT Excluding Unusual Items | -258.76 | -157.86 | -128.93 | -104.19 | -68.64 | |
| Legal Settlements | - | - | -12.5 | -15 | - | |
| Other Unusual Items | - | - | - | 6.86 | 1.41 | |
| Pretax Income | -258.76 | -157.86 | -141.43 | -112.33 | -70.74 | |
| Income Tax Expense | - | - | - | - | -0.23 | |
| Net Income | -258.76 | -157.86 | -141.43 | -112.33 | -70.51 | |
| Net Income to Common | -258.76 | -157.86 | -141.43 | -112.33 | -70.51 | |
| Shares Outstanding (Basic) | 66 | 64 | 48 | 47 | 43 | |
| Shares Outstanding (Diluted) | 66 | 64 | 48 | 47 | 43 | |
| Shares Change (YoY) | 3.15% | 32.91% | 3.33% | 9.37% | 44.64% | |
| EPS (Basic) | -3.90 | -2.45 | -2.92 | -2.40 | -1.64 | |
| EPS (Diluted) | -3.90 | -2.45 | -2.92 | -2.40 | -1.64 | |
| Free Cash Flow | -213.66 | -159.7 | -109.11 | -105.56 | -62.16 | |
| Free Cash Flow Per Share | -3.22 | -2.48 | -2.25 | -2.25 | -1.45 | |
| Operating Margin | -18599.81% | -2778.89% | -2063.66% | -4543.74% | -1486.73% | |
| Profit Margin | -16748.03% | -2248.76% | -2054.76% | -4765.59% | -1516.04% | |
| Free Cash Flow Margin | -13829.06% | -2274.89% | -1585.19% | -4478.57% | -1336.44% | |
| EBITDA | -283.99 | -191.9 | -139.03 | -104.2 | -66.08 | |
| D&A For EBITDA | 3.38 | 3.18 | 3.01 | 2.9 | 3.07 | |
| EBIT | -287.37 | -195.08 | -142.04 | -107.1 | -69.15 | |
| Revenue as Reported | 1.55 | 7.02 | 6.88 | 2.36 | 4.65 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.